Craig van Horne, MD, PhD
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Craig van Horne, MD, PhD sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Craig van Horne, MD, PhD: 5 sponsored US clinical trials, 2 recruiting.
Craig van Horne, MD, PhD sponsors 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Parkinson's Disease, with 4 trials.
Upper-quartile sponsor footprint
Craig van Horne, MD, PhD sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
A Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery
NCT06683378
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
NCT06683365
Feasibility and Safety of autoloGous UncondItioneD pEripheral Nerve Tissue Delivery to the Substantia Nigra (GUIDE)
NCT05377281
Cont. of a Study to Evaluate Implanting Peripheral Nerve Grafts Into Subjects With Parkinson's Disease (PD) During DBS
NCT02369003
Autologous Peripheral Nerve Grafts Into the Substantia Nigra of Subjects With PD Undergoing Deep Brain Stimulation
NCT01833364
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
Therapeutic Areas
What is open in the Craig van Horne, MD, PhD pipeline
2 recruiting of 5 indexed (40% open); 1 completed (20%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Parkinson's Disease (4 trials), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Craig van Horne, MD, PhD: open-pipeline peers nationwide
Peers matched on 5 registered trials and 40% open enrollment, not the therapeutic-area sidebar.
Craig van Horne, MD, PhD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 40% open enrollment (± trial volume)
- Ad scientiam · 40% recruiting · 5 trials
- Alto Neuroscience · 40% recruiting · 10 trials
- Bonafide Health · 40% recruiting · 5 trials
- Brooks Rehabilitation · 40% recruiting · 5 trials
Related
What to do with this Craig van Horne, MD, PhD page
5 registered trials is a research-attention snapshot, not an endorsement of Craig van Horne, MD, PhD or any single study.
- 2 of Craig van Horne, MD, PhD's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Parkinson's Disease is the condition Craig van Horne, MD, PhD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Parkinson's Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Craig van Horne, MD, PhD pipeline card: 5 registered trials from official public datasets.Report a data error.